In vitro screening on Alpha amylase and Alpha glucosidase inhibitory activities of some novel Quinazolinone derivatives

Abstract

Diabetes mellitus is a metabolic condition characterised by chronic hyperglycaemia, and type II diabetes is the most common type, accounting for 90% of cases globally. Hyperglycaemia is major complication of Diabetes mellitus. Postprandial hyperglycaemia is the most common distinctive of diabetes. Inhibition of carbohydrate hydrolysing enzymes including amylase and glucosidase may be useful method for lowering postprandial blood sugar levels. Alpha amylase and glucosidase inhibitors are the most approaching targets in the development of lead compounds for the treatment and management of diabetes. This type of inhibitors, used in clinical practise for the treatment of diabetes are known to be associated with gastrointestinal side effects. Therefore, we need to synthesize new compounds which have fewer side effects. In present study synthesized thirty quinazolinone compounds (PM1-PM30) were screened for their inhibitory effect on alpha amylase and alpha glucosidase enzymes. All synthesized compounds PM1 to PM 30, possess good inhibitory activity similar to that of approved drug Acarbose. Compounds PM20 PM7, PM28, PM29 are remarkable potent alpha amylase inhibitors and compounds PM30, PM28, PM29, PM4 are remarkable potent alpha glucosidase inhibitors. Therefore, these compounds are beneficial for management and treatment of diabetes disorder.